Reuters logo
BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept
April 10, 2017 / 12:14 PM / 8 months ago

BRIEF-Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept

April 10 (Reuters) - Oncomed Pharmaceuticals Inc

* Oncomed Pharmaceuticals announces Bayer terminates its option to license vantictumab or ipafricept

* Oncomed - Bayer Pharma notified co of decision not to exercise option to license WNT pathway inhibitors vantictumab, ipafricept for strategic reasons

* Oncomed - Effective June 2017, co to retain worldwide development & commercialization rights to vantictumab, ipafricept, WNT pathway biologics

* Oncomed Pharmaceuticals Inc - small molecule program under companies’ collaboration continues without change

* Oncomed - will be conducting internal portfolio review and prioritization to determine next steps for all programs, including vantictumab, ipafricept Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below